{"type":"trials","record":{"id":41825,"source_id":"clinicaltrials-gov","external_id":"NCT06888492","title":"To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)","brief_summary":"The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of EXG202 in subjects with neovascular age-related Macular Degeneration (nAMD).","overall_status":"Not Yet Recruiting","phases":["EARLY_PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Guangzhou Jiayin Biotech Ltd","enrollment":8,"countries":["China"],"start_date":"2025-03-28","completion_date":"2026-04-30","last_update_date":"2025-03-21","source_url":"https://clinicaltrials.gov/study/NCT06888492","editorial_summary":"A registered EARLY_PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Guangzhou Jiayin Biotech Ltd","interventions":["EXG202"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety and tolerability after EXG202 injection — up to 52 weeks after treatment","To evaluate the efficacy after EXG202 injection — up to 52 weeks after treatment","To evaluate the efficacy after EXG202 injection — 52 weeks following EXG202 treatment."],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration (wAMD)","Wet Age-related Macular Degeneration","EXG202"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06888492","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-03-28 to 2026-04-30","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.877Z","intervention":["EXG202"],"participants":8,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"EARLY_PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety and tolerability after EXG202 injection — up to 52 weeks after treatment","To evaluate the efficacy after EXG202 injection — up to 52 weeks after treatment","To evaluate the efficacy after EXG202 injection — 52 weeks following EXG202 treatment."],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41825","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}